Clinical Trials Logo
  1. Home
  2. Lymphoma, Non-Hodgkin's
  3. NCT00384150

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin's Clinical Trial

Official title:
A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301

Clinical Trial Summary

This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory, follicular NHL who demonstrated a response on Study 114-NH-301 with a time-to-progression >=6 months.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00384150
Study type Interventional
Source Biogen
Contact
Status Terminated
Phase Phase 3
Start date November 2007
Completion date January 2010
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00363636 - A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT02518750 - Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Phase 2
Completed NCT01733238 - Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00141700 - Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00143884 - Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Phase 2
Completed NCT02750670 - Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 2
Terminated NCT02473523 - Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia N/A
Completed NCT00413036 - A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma Phase 2
Completed NCT00161590 - Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Phase 1
Terminated NCT00651443 - Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04756726 - Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Phase 1/Phase 2
Terminated NCT00395967 - AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone Phase 2
Completed NCT00143871 - Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma Phase 2